

16 November 2007

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254,
Wellington 6143, New Zealand

To all interested parties

Phone 64-4-460-4990

Fax 64-4-460-4995

www.pharmac.govt.nz

Consultation on a proposal regarding doxepin hydrochloride and salbutamol

PHARMAC and Pacific Pharmaceuticals have entered into a provisional agreement regarding doxepin hydrochloride (Anten) and salbutamol (Respigen), and PHARMAC is seeking feedback on this proposal.

Outline of proposal

Under this proposal, there would be:

- a price and subsidy increase for doxepin hydrochloride (Anten), with the effect that all available presentations would be fully subsidised;
- a listing of Respigen as an alternative salbutamol aerosol inhaler; and
- reference pricing of the Salamol and Ventolin brands of salbutamol aerosol inhaler to Respigen.

Further details of this proposal are provided below.

Feedback sought

PHARMAC welcomes feedback on this proposal. If you wish to submit feedback on this proposal please submit them in writing by 30 November 2007 to:

Sean Dougherty
Therapeutic Group Manager
PHARMAC
PO Box 10-254
Wellington 6143

Email: Sean.Dougherty@pharmac.govt.nz

Fax: (04) 460 4995

Details of proposal

- The price and subsidy for doxepin hydrochloride (Anten) would be increased as follows from 1 February 2008 (ex-manufacturer, excluding GST):

Chemical	Formulation	Pack size	Current subsidy (price, if different from subsidy)	Proposed subsidy and price
Doxepin hydrochloride	Cap 10 mg	100	\$4.99	\$5.24
Doxepin hydrochloride	Cap 25 mg	100	\$4.19 (\$5.20)	\$5.46
Doxepin hydrochloride	Cap 50 mg	100	\$6.99	\$7.34

- Please note that manufacture of the 75 mg capsule of doxepin hydrochloride has been discontinued and will likely be unavailable from 1 July 2008 (delisted from the Pharmaceutical Schedule from 1 January 2009).
- Respigen (salbutamol) would be listed in Section B of the Pharmaceutical Schedule from 1 June 2008 at the following price and subsidy (ex-manufacturer, excluding GST):

Chemical	Brand	Formulation	Pack size	Proposed subsidy and price
Salbutamol	Respigen	Aerosol inhaler, 100 µg per dose CFC-free	200 dose OP	\$3.80

- PHARMAC would reduce the subsidy payable for the existing brands of salbutamol aerosol inhaler by reference pricing them to Respigen from 1 June 2008 as follows:

Chemical	Brand	Formulation	Pack size	Current subsidy (price, if different from subsidy)	Proposed subsidy
Salbutamol	Salamol	Aerosol inhaler, 100 µg per dose CFC-free	200 dose OP	\$4.00	\$3.80
Salbutamol	Ventolin	Aerosol inhaler, 100 µg per dose CFC-free	200 dose OP	\$4.00 (\$6.00)	\$3.80

If you have any questions in relation to this proposal, please contact me on (04) 916 7534 or by email: Sean.Dougherty@pharmac.govt.nz.

Yours sincerely



Sean Dougherty
Therapeutic Group Manager